Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
The SMILE trial will seek to identify individuals at high risk for developing lupus and treat them before they ever transition into the disease.
Osteoarthritis is the most common form of disability in the U.S., but you might find an ally against it in the produce section.
The Scheinberg Award recognizes research excellence in the field of neurorehabiliation in MS.
New research will help physicians better identify blood relatives of lupus patients at risk for developing the disease.